The immune system - A double-edged sword for adenovirus-based therapies

Wallace, Rebecca, Bliss, Carly M. and Parker, Alan L. ORCID: https://orcid.org/0000-0002-9302-1761 2024. The immune system - A double-edged sword for adenovirus-based therapies. Viruses 16 (6) , 973. 10.3390/v16060973

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Pathogenic adenovirus (Ad) infections are widespread but typically mild and transient, except in the immunocompromised. As vectors for gene therapy, vaccine, and oncology applications, Ad-based platforms offer advantages, including ease of genetic manipulation, scale of production, and well-established safety profiles, making them attractive tools for therapeutic development. However, the immune system often poses a significant challenge that must be overcome for adenovirus-based therapies to be truly efficacious. Both pre-existing anti-Ad immunity in the population as well as the rapid development of an immune response against engineered adenoviral vectors can have detrimental effects on the downstream impact of an adenovirus-based therapeutic. This review focuses on the different challenges posed, including pre-existing natural immunity and anti-vector immunity induced by a therapeutic, in the context of innate and adaptive immune responses. We summarise different approaches developed with the aim of tackling these problems, as well as their outcomes and potential future applications.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	MDPI
ISSN:	1999-4915
Funders:	Cancer Research UK
Date of First Compliant Deposit:	18 June 2024
Date of Acceptance:	14 June 2024
Last Modified:	20 Jun 2024 11:35
URI:	https://orca.cardiff.ac.uk/id/eprint/169870

Actions (repository staff only)

Edit Item